PubMed Health⌕ Search

Biomedical subjects

S Papper

Publications and source records attributed to S Papper.

At least 19 recordsLinked to original sources

Arginine-induced hypermagnesemia and hyperkalemia in nephrectomized rats.

This study examined the effect of arginine monohydrochloride infusion on serum Mg and K in nephrectomized rats. Hyperkalemia exceeded the hypermagnesemia both of which occurred in response to arginine infusion and/or metabolic acidosis. This observation is consonant with our earlier reports which demonstrated that the activity of K exceeded that of Mg in shifts between the intracellular and extracellular compartments under a variety of experimental conditions.

Acidosis↗

Nephrotic syndrome and neoplasm. The findings to date, with practical implications.

The following points should be kept in mind in cases of nephrotic syndrome. Neoplasm (malignant or benign) occurs in approximately 10% of adults with nephrotic syndrome (15% of those over age 60). The neoplasm may be evident before, after, or simultaneously with the development of the nephrotic syndrome. Minimal change lesion in the kidney suggests possible Hodgkin's disease, while membranous nephropathy is more suggestive of possible carcinoma, although there are many exceptions to this generalization. Membrano-proliferative and focal sclerosis renal lesions also occur with diverse tumors. Strong evidence exists that in cases of carcinoma and nephrotic syndrome, the renal lesion is generally due to immune complexes--either tumor-associated antigens, fetal antigens, or viral antigens. In cases involving Hodgkin's disease, T-cell deficiency may be relevant in the genesis of the minimal change lesion and the nephrotic syndrome. Nephrotic syndrome often responds to effective treatment of the tumor and commonly recurs with relapse of the neoplasm. Nephrotic syndrome without apparent cause in an adult compels consideration of an associated neoplasm.

Antigen-Antibody Complex↗

Intravenous magnesium--potential hazard of inadequate mixing.

Failure to mix 24.5 mM of magnesium, added as 50% MgSO4 in 1 liter of intravenous fluid, results in a high concentration of Mg in the initial 10-cc aliquot: 1,145.7 mM/liter. Adequate dispersion can be obtained after three inversions. We conclude that because of the extremely high concentrations of Mg that can result if no mixing is done, it is imperative that hospital personnel ensure that added Mg is adequately dispersed in intravenous fluid prior to administration. A method of signalling the inadequacy of mixing is to color code additives with a harmless dye to alert personnel to the problem of inadequate dispersement.

Coloring Agents↗

High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia.

To evaluate the efficacy and safety of a simple approach to intravenous phosphorus therapy, we prospectively studied ten adult patients with severe hypophosphatemia (less than or equal to 1 mg/dl), two or more clinical reasons for the hypophosphatemia, and normal renal function. They were treated with a solution containing 0.32 mmol of phosphorus per kilogram of body weight. This amount of phosphorus was infused intravenously over 12 hours and repeated every 12 hours until the serum phosphorus was greater than or equal to 2 mg/dl. The serum phosphorus, potassium, magnesium, and calcium levels were measured at six hours, 12 hours, and every 12 hours thereafter. The serum phosphorus level was greater than or equal to 2 mg/dl in one patient at six hours, three patients at 12 hours, three patients at 24 hours, four patients at 36 hours, and one patient at 48 hours. The serum calcium was measured every 12 hours and at no time was any patient dangerously hypocalcemic. Administration of 0.32 mmol of phosphorus per kilogram of body weight intravenously over a 12-hour period is both efficacious and safe in severely hypophosphatemic patients with multiple causes of hypophosphatemia, normal renal function, and no hypercalcemia.

Adult↗

Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient.

To evaluate the efficacy and safety of a simple approach to intravenous (IV) phosphorus therapy, ten adult patients with severe hypophosphatemia (less than or equal to 1 mg/dL) and normal renal function were studied prospectively. They were treated with a solution containing 9 mmole of phosphorus as monobasic potassium phosphate (KH2PO4), infused continuously every 12 hours. Serum phosphorus, potassium, and calcium levels and urinary excretion of phosphorus were measured every 12 hours. The serum phosphorus level was significantly improved at 12 hours, more than 1 mg/dL in all patients at 36 hours, and normal in six patients at 48 hours. The serum potassium level was never above normal, and serum calcium levels declined in only one patient. Administration of 9 mmole of phosphorus as KH2PO4 every 12 hours is both safe and efficacious IV therapy for severe hypophosphatemia in the adult patient with normal renal function and without hyperkalemia or hypercalcemia.

Acute Disease↗

The clinical spectrum of renal vein thrombosis: acute and chronic.

The present study is a prospective evaluation of 151 patients with the nephrotic syndrome in regard to the incidence of renal vein thrombosis, modes of clinical presentation, pathogenetic course and response to anticoagulant therapy. Of the 151 nephrotic patients studied, 33 had renal vein thrombosis and membranous nephropathy was present in 20. There were two modes of clinical presentation: (1) a sudden renal vein thrombosis was observed in the young patient with acute flank pain, marked costovertebral angle tenderness and macroscopic hematuria; a characteristic intravenous pyelogram, renal histologic changes and anticoagulant therapy were followed by marked improvement in renal function; (2) long-term renal vein thrombosis was observed in the older patients; they were asymptomatic and intravenous pyelograms disclosed no abnormalities; there were no suggestive renal histologic findings; the incidence of thromboembolic phenomena other than renal vein thrombosis was high, and there was mild progressive deterioration of renal function which was not altered by anticoagulant drugs; treated nephrotic patients with chronic renal vein thrombosis did not experience a new episode of thromboembolism whereas untreated nephrotic patients without renal vein thrombosis did. Finally, the sequence of nephrotic syndrome leading to renal vein thrombosis was clearly established showing the pathogenetic role of the nephrotic syndrome in renal vein thrombosis. Possible mechanisms in the pathogenesis of renal vein thrombosis are also discussed.

Acute Disease↗

Hepatorenal syndrome.

Renal failure without apparent cause (the hepatorenal syndrome) may develop in the course of cirrhosis of the liver. While the development of renal failure bears a poor prognosis, spontaneous recovery can occur. The data suggest that for the most part patients die in rather than of renal failure. The latter seems to be only part of a broader more fundamental disturbance. The pathogenesis of HRS is unknown, but the evidence supports an impairment of effective renal perfusion. The two major hypotheses concerning the nature of the impaired perfusion are that it is a physiologic response to alterations in the extrarenal circulation, and that there is an unidentified humoral agent(s) produced by or inadequately inactivated by or bypassing the diseased liver and causing circulatory changes in the kidney as well as in other organs. It is possible that both mechanisms are operative. Treatment is unsatisfactory and emphasis is presently best placed upon searching for more treatable causes of renal functional impairment in individual patients.

Humans↗

Interstitial nephritis.

There are many causes of interstitial nephritis other than pyelonephritis. The term interstitial nephritis does not connote a single etiologic or pathogenetic mechanism; it rather arbitrarily places together a wider variety of renal diseases that have a predilection for early and major involvement of the renal interstitium. The prototype of acute interstitial nephritis is acute pyelonephritis. In addition, there is a drug-related acute interstitial disease that is probably of immunological nature and usually reverses with discontinuance of the offending drug. Chronic interstitial nephritis includes many diverse illnesses. Nonobstructive pyelonephritis occurs but its prevalence is debated. Analgesic abuse nephropathy is not rare and is potentially reversible. Papillary necrosis has many causes and a wide spectrum of clinical presentations. Heavy metals, such as lead, cause interstitial nephritis. Balkan nephropathy occurs in an endemic area and although not bacterial in origin is of unknown cause.

Diagnosis, Differential↗

Circulating levels of vasoactive intestinal polypeptide in liver disease.

In animals, the effects of vasoactive intestinal polypeptide (VIP) include peripheral vasodilation, hyperdynamic circulation, hyperglycemia, and hyperventilation. Because these phenomena are noted in patients with cirrhosis, it has been postulated that VIP might be escaping hepatic inactivation and entering the systemic circulatory system and contributing to these abnormalities. The major purpose of this study is to establish whether or not VIP levels are elevated in patients with cirrhosis. Additional goals are to determine if VIP levels are elevated in acute liver disease and in chronic illnesses with secondary liver involvement. The data demonstrate that patients with cirrhosis and those with acute liver disease or chronic illnesses with secondary hepatic involvement have a wide range of VIP levels with mean values significantly above that of normal individuals and patients with chronic illness and no liver involvement.

Acute Disease↗